Clinical trial

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

NCT03095638

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-05-03

PhasePHASE1

Study timeline

Study start (actual)2017-05-03Date precision: day

Registry last updated2019-07-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

Conventional dolutegravir 10 mg tabletDRUG

Conventional dolutegravir 50 mg tabletDRUG

Dispersible dolutegravir 5 mg tabletDRUG

Conventional dolutegravir 25 mg tabletDRUG

Sponsors & collaborators

ViiV Healthcarelead sponsor

GlaxoSmithKlinecollaborator

Mapped research locations

AustinTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03095638 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.